AB0124 is a serotonin 5-HT<sub>2A</sub> receptor positive allosteric modulator. It is highly selective for potentiation of the serotonin 5-HT<sub>2A</sub> receptor, with no potentiation of the serotonin 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors. In addition, it showed no orthosteric agonistic activity at any of the serotonin 5-HT<sub>2</sub> receptors. AB0124 has been studied in combination with the serotonin 5-HT<sub>2</sub> receptor agonist (R)-DOI in animal models of cocaine use disorder. The chemical synthesis of AB0124 has been described. The drug was patented in 2022 and was first described in the scientific literature by 2024.